Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL3 | P20749 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17554022 | 0.92 | BCL3 (0.85) | BCL3KMT2AHTTALDH1A1GAA | |
| SCHEMBL16431762 | 0.91 | BCL3 (1.00) | BCL3KMT2AHTTALDH1A1GAA | |
| SCHEMBL29849775 | 0.91 | BCL3 (1.00) | BCL3KMT2AHTTALDH1A1GAA | |
| SCHEMBL17554162 | 0.89 | BCL3 (0.80) | BCL3KMT2AHTTALDH1A1GAA | |
| SCHEMBL19348436 | 0.89 | BCL3 (0.80) | BCL3KMT2AHTTALDH1A1GAA | |
| SCHEMBL30560485 | 0.89 | BCL3 (0.80) | BCL3KMT2AHTTALDH1A1GAA | |
| SCHEMBL30560522 | 0.89 | BCL3 (0.80) | BCL3KMT2AHTTALDH1A1GAA | |
| SCHEMBL17554066 | 0.88 | BCL3 (0.78) | BCL3KMT2AHTTALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL17554124 | 0.87 | BCL3 (0.76) | BCL3KMT2AHTTALDH1A1GAA | |
| SCHEMBL29849939 | 0.86 | BCL3 (0.82) | BCL3KMT2AHTTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027594-B1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-08-10 | — | — | EP | claimed |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-01-20 | — | — | US | claimed |
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2021-11-23 | — | — | US | claimed |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2020-01-30 | — | — | US | claimed |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-10-22 | — | — | US | claimed |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-06-30 | — | — | US | claimed |
| EP-3027594-B1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-08-10 | — | — | EP | disclosed |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-01-20 | — | — | US | disclosed |
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2020-01-30 | — | — | US | disclosed |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | BCL3 1/4885KMT2A 905/4885HTT 3969/4885 |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | BCL3 1/4885KMT2A 905/4885HTT 3969/4885 |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | BCL3 1/4885KMT2A 1055/4885HTT 3891/4885 |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | BCL3 1/4885KMT2A 1055/4885HTT 3891/4885 |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | BCL3 1/4885KMT2A 1055/4885HTT 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.